针对抗癌疗法的PI3激酶抑制剂的早期开发阶段
Carlo Caputo1,2, Angela Lombardi2,3, Margherita Vicario1
1Laboratory of Molecular and Precision Oncology, Institute of Genetic Research, Biogem Scarl, Ariano Irpino, Italy.
Expert opinion on investigational drugs
|October 28, 2025
概括
PI3K/Akt/mTOR通路对细胞功能至关重要,但其异常激活会导致癌症. PI3KCA遗传变化很常见,使PI3KCA抑制剂成为有前途的癌症治疗方法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- PI3K/Akt/mTOR通路调节细胞增殖,生存和新陈代谢.
- 这种途径的异常激活驱动瘤的发展和进展.
- 编码p110α亚单元的PI3KCA的遗传变化是各种癌症中常见的致癌特征.
研究的目的:
- 审查目前关于PI3K/Akt/mTOR通路的知识,重点关注PI3KCA在瘤发生中的遗传变化.
- 讨论PI3KCA抑制剂在不同癌症类型中的治疗潜力.
- 要突出与PI3KCA抑制剂治疗相关的局限性和挑战.
主要方法:
- 关于PI3K/Akt/mTOR通路和PI3KCA遗传变化的文献综述.
- 已批准和正在研究的PI3KCA抑制剂的分析.
- 讨论PI3KCA抑制剂的临床结果,疗效和毒性.
主要成果:
- 在许多癌症中,PI3KCA突变/放大是普遍存在的,确定PI3KCA是关键的治疗标.
- PI3KCA抑制剂显示出作为针对突变p110α的瘤的向治疗的前景.
- 当前的挑战包括管理患者的疗效和毒性.
结论:
- 特定PI3KCA抑制剂为特定癌症类型提供了一种新的治疗策略.
- 优化治疗需要通过基因组分析对患者进行分子分层.
- 开发有针对性的组合疗法对于最大化益处和改善患者治疗结果至关重要.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
Phosphoinositides and PIPs
10.1K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
10.1K
The JAK-STAT Signaling Pathway
11.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.9K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
IP3/DAG Signaling Pathway
14.2K
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
14.2K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K


